Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Therapeutic Strategies and Targets to Improve the Efficacy of PD-1/PD-L1 Blockade"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 June 2023 | Viewed by 5592
Special Issue Editor
Interests: cancer immunotherapy; immune checkpoint; tumor microenvironment; vaccine; peptide
Special Issue Information
Programmed cell death protein 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) are the hottest drug targets in cancer immunotherapy. Increasing numbers of researches are focusing on the combination therapies to cope with the low average response rate of PD-1/PD-L1 antibody blockade therapy in cancer and other indications. The combinational strategies include the use of Toll-like receptor (TLRs) and STING agonist vaccines, cytokines, nanomedicines, radiotherapy or chemotherapy to activate the innate immunity or induce tumor cell death. In addition, the combination with various targets and their drugs to achieve the purpose of activating innate and adaptive immunity are ongoing. These targets may play a role from different perspectives, such as the phagocytic targets CD47/SIRPa and CD24/Siglec-10 that modulate the function of macrophages, the NKG2 and KIR members that affect the function of NK cells, the targets hinder the function of immunosuppressive MDSC or Treg cells, CD73 and CD39 affects the adenosine metabolism, CD36 and CD38 that regulate the lipid metabolism, and the angiogenesis signaling VEGF/VEGFRs that affects the vascular angiogenesis and normalization to impact the infiltration of immune cells in tumor microenvironment. Drugs of these targets may focus on not only antibodies, but the fusion proteins, peptide drugs, small molecule drugs, aptamers, PROTAC and nanomedicines.
This Special Issue aims to improve the efficacy of PD-1/PD-L1 blockade in cancer and expand the knowledge on a wide range of topics in this field. The journal Pharmaceuticals now invites you to contribute review or original research articles covering the different facets of the combination therapy, which will be published as a Special Issue on “Therapeutic Strategies and Targets to Improve the Efficacy of PD-1/PD-L1 Blockade”.
Prof. Dr. Yanfeng Gao
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint
- targeted therapy